Clinical Trial Search

Primary: First Occurrence of the Composite of Failed First Appropriate Clinical Shock From the Implantable Cardioverter Defibrillator (ICD) or Arrhythmic Death — 90; 104…

Primary: Change in Glycosylated Haemoglobin (HbA1c) From Baseline — -1.809; -1.238 Percent (%) glycosylated haemoglobin

Primary: Percent Change From Baseline in LDL-C at Week 12 — -18.08; -15.05; -56.14; -52.60 percent change — p=<0.001

Primary: Medroxyprogesterone Acetate (MPA) Pharmacokinetic Parameter (PK) Area Under the Concentration-time Curve (AUC0-12weeks) — 18.08 ng*wk/mL

Primary: Change From Baseline in Glycosylated Haemoglobin (HbA1c) — -1.666; -0.969 Percent (%) glycosylated haemoglobin

Primary: Cmax - Maximum Observed Plasma Concentration (BIA 9-1067 + Warfarin) — 196 ng/mL

Primary: Progression-free Survival Rate — 1.759 years

Primary: Cmax - Maximum Observed Plasma Concentration (L-DOPA) — 1070; 1105; 1198 ng/mL

Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 — 9.86; 0.97; -21.96; -17.08 percent change — p=<0.001

Primary: Percent Change From Baseline in LDL-C at Week 12 — -2.02; 5.53; -61.25; -55.74 percent change — p=<0.001

Primary: Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Nintedanib — 0; 0; 0; 0 participants

Primary: Visual Distortion Symptoms — 0.89; 0.38; 0.64; 0.38 rating of visual distortion symptoms

Primary: Number of Participants With Local Adverse Events as a Measure of Safety and Tolerability — 15; 7; 14; 13 participants — p=0.12

Primary: Conversion to Sinus Rhythm — 4; 4; 11; 13 participants

Primary: Diagnostic Performance: Concordance Between Investigational Allergen and Reference Allergen at Day 21 — 78.9 percentage of concordant responses